Nature Communications (Apr 2018)
Treating cat allergy with monoclonal IgG antibodies that bind allergen and prevent IgE engagement
- J. M. Orengo,
- A. R. Radin,
- V. Kamat,
- A. Badithe,
- L. H. Ben,
- B. L. Bennett,
- S. Zhong,
- D. Birchard,
- A. Limnander,
- A. Rafique,
- J. Bautista,
- A. Kostic,
- D. Newell,
- X. Duan,
- M. C. Franklin,
- W. Olson,
- T. Huang,
- N. A. Gandhi,
- L. Lipsich,
- N. Stahl,
- N. J. Papadopoulos,
- A. J. Murphy,
- G. D. Yancopoulos
Affiliations
- J. M. Orengo
- Regeneron Pharmaceuticals Inc.
- A. R. Radin
- Regeneron Pharmaceuticals Inc.
- V. Kamat
- Regeneron Pharmaceuticals Inc.
- A. Badithe
- Regeneron Pharmaceuticals Inc.
- L. H. Ben
- Regeneron Pharmaceuticals Inc.
- B. L. Bennett
- Regeneron Pharmaceuticals Inc.
- S. Zhong
- Regeneron Pharmaceuticals Inc.
- D. Birchard
- Regeneron Pharmaceuticals Inc.
- A. Limnander
- Regeneron Pharmaceuticals Inc.
- A. Rafique
- Regeneron Pharmaceuticals Inc.
- J. Bautista
- Regeneron Pharmaceuticals Inc.
- A. Kostic
- Regeneron Pharmaceuticals Inc.
- D. Newell
- Regeneron Pharmaceuticals Inc.
- X. Duan
- Regeneron Pharmaceuticals Inc.
- M. C. Franklin
- Regeneron Pharmaceuticals Inc.
- W. Olson
- Regeneron Pharmaceuticals Inc.
- T. Huang
- Regeneron Pharmaceuticals Inc.
- N. A. Gandhi
- Regeneron Pharmaceuticals Inc.
- L. Lipsich
- Regeneron Pharmaceuticals Inc.
- N. Stahl
- Regeneron Pharmaceuticals Inc.
- N. J. Papadopoulos
- Regeneron Pharmaceuticals Inc.
- A. J. Murphy
- Regeneron Pharmaceuticals Inc.
- G. D. Yancopoulos
- Regeneron Pharmaceuticals Inc.
- DOI
- https://doi.org/10.1038/s41467-018-03636-8
- Journal volume & issue
-
Vol. 9,
no. 1
pp. 1 – 15
Abstract
Allergen-specific immunotherapy is used to treat patients affected by acute immunoglobulin E (IgE) responses, but the function mechanism is unclear. Here the authors show that the administration of two cat allergen-specific IgGs reduces allergic responses in mouse models and helps ameliorate clinical symptoms in a phase 1b clinical trial.
